Vyne Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
VYNE Therapeutics announced a definitive merger agreement with Yarrow Biosciences, shifting its strategic focus to Yarrow's clinical-stage TSHR antibody for Graves Disease, following setbacks in its BET inhibitor programs.
NASDAQ
VYNE Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical development programs, including repibresib gel and VYN202.
NASDAQ
VYNE Therapeutics Inc. reports its 2023 financial results and provides updates on its clinical-stage immuno-inflammatory drug development programs, including VYN201 and VYN202.